Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

256
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
256
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

395
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
395
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

701
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
701
Chronic Pancreatitis I: Introduction01:24

Chronic Pancreatitis I: Introduction

624
The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
624
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

396
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
396
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

1.5K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aspirin Use and Liver-Related Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis.

Biomedicines·2026
Same author

Long-Term Outcomes of Fenofibrate for Treatment of Ischemic Cholangiopathy in Donation After Circulatory Death Liver Transplantation.

Clinical transplantation·2025
Same author

Exploring Varied Treatment Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

Life (Basel, Switzerland)·2024
Same author

Long-term clinical outcomes of patients with COVID-19 and chronic liver disease: US multicenter COLD study.

Hepatology communications·2023
Same author

Special Considerations in the Management of HIV and Viral Hepatitis Coinfections in Liver Transplantation.

Hepatic medicine : evidence and research·2022
Same author

Update on Emerging Treatment Options for Primary Biliary Cholangitis.

Hepatic medicine : evidence and research·2020
Same journal

METTL3/FTO drives ferroptosis in colorectal cancer by targeting m<sup>6</sup>A modification of MUC1 mRNA and YTHDF2-dependent SLC7A11/GSH pathway.

Journal of gastroenterology·2026
Same journal

Risk of lymph-node metastasis in early onset T1 colorectal cancer: a systematic review and meta-analysis.

Journal of gastroenterology·2026
Same journal

Clinical characteristics of acute pancreatitis in patients with inflammatory bowel disease: a nationwide survey in Japan.

Journal of gastroenterology·2026
Same journal

Vonoprazan is associated with a phenotype-specific increase in cholangitis reporting in immune checkpoint inhibitor-treated patients: a VigiBase pharmacovigilance study.

Journal of gastroenterology·2026
Same journal

Alcohol involvement may modify the association between previous hepatitis B virus infection and hepatocellular carcinoma risk in steatotic liver disease.

Journal of gastroenterology·2026
Same journal

Stage-associated remodeling of CD169 macrophage states is linked to immune regulation in colitis-associated colorectal cancer.

Journal of gastroenterology·2026
See all related articles

Related Experiment Video

Updated: Dec 30, 2025

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis
04:38

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis

Published on: March 28, 2018

16.4K

Emerging therapies for PBC.

David Maxwell Hunter Chascsa1,2, Keith Douglas Lindor3

  • 1Department of Gastroenterology and Hepatology, Mayo Clinic, MD 5777 E. Mayo Blvd, Phoenix, AZ, 85054, USA. chascsa.david@mayo.edu.

Journal of Gastroenterology
|January 24, 2020
PubMed
Summary
This summary is machine-generated.

New therapies are needed for primary biliary cholangitis, a serious liver disease. Fibrates show promise, improving surrogate and clinical endpoints for patients with this uncommon condition.

Keywords:
FibrateLiver diseaseObeticholic acidPrimary biliary cholangitisUrsodeoxycholic acid

More Related Videos

A Mouse Model of Chronic Liver Fibrosis for the Study of Biliary Atresia
09:12

A Mouse Model of Chronic Liver Fibrosis for the Study of Biliary Atresia

Published on: February 3, 2023

3.1K

Related Experiment Videos

Last Updated: Dec 30, 2025

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis
04:38

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis

Published on: March 28, 2018

16.4K
A Mouse Model of Chronic Liver Fibrosis for the Study of Biliary Atresia
09:12

A Mouse Model of Chronic Liver Fibrosis for the Study of Biliary Atresia

Published on: February 3, 2023

3.1K

Area of Science:

  • Hepatology
  • Cholestatic Liver Diseases
  • Drug Development

Background:

  • Primary biliary cholangitis (PBC) is a rare cholestatic liver disease primarily affecting middle-aged women.
  • Untreated PBC can lead to end-stage liver disease, with limited therapeutic options currently available.
  • Ursodeoxycholic acid (UDCA) and obeticholic acid (OCA) are approved treatments, but many patients lack adequate response.

Purpose of the Study:

  • To evaluate the potential of new therapeutic agents for primary biliary cholangitis.
  • To address the challenges in evaluating PBC therapies, including disease heterogeneity and lengthy endpoint development.

Main Methods:

  • Review of current and emerging treatment strategies for PBC.
  • Analysis of clinical trial data assessing surrogate and clinical endpoints for PBC therapies.
  • Focus on the evaluation of fibrates as a novel therapeutic class.

Main Results:

  • Fibrates have demonstrated beneficial effects on surrogate endpoints in PBC.
  • Emerging data suggest that fibrates are beginning to show improvements in clinical endpoints.
  • Challenges in PBC trial evaluation include disease heterogeneity and the need for standardized response criteria.

Conclusions:

  • Fibrates represent a promising new therapeutic avenue for primary biliary cholangitis.
  • Further research and long-term data are necessary to fully establish the role of fibrates in PBC management.
  • Addressing evaluation challenges is crucial for accelerating the development of effective PBC treatments.